Søgning på udtrykket 'paxlovid' giver 45 resultater
Dokumenter [4] Kalender [1] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
Dokumenter [4]
Ændringer siden version 28: Moderat risikogruppe udgår. Gravide udgår som risikogruppe. Skærpelse af kriterier for opstart af Paxlovid (nu kun højrisiko patient med indikation).
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau. Ændringer i denne udgave: Remdesivir står ikke længere som relativt kontraindiceret ved påvirket nyrefunktion.
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau. Ændringer i denne udgave: 1. Et af Paxlovid kriterierne ændret (fra ”Betydelige symptomer på COVID-19” til ”Mild eller moderat COVID-19”). 2. Døde links til infektionshygiejniske retningslinjer er fjernet, og nyt er indsat. 3. Tekst om afisolation.
Ændringer siden sidste udgave: 1. Simplificering af risikogrupper. 2. Skærpelse af kriterier for opstart af behandling hos indlagte patienter, f.eks. blodgas analyse før remdesivir. 3. Information om høj pris på paxlovid og højere NNT for beskyttelse mod alvorligt forløb siden primærpublikation.
Kalender [1]
11. oktober 2022, Online
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Journal of the American Medical Association
21.02.2024
This Medical News story examines the latest information about rebound, treatment eligibility, optimal dosing, and other questions related to nirmatrelvir-ritonavir for treating COVID-19.
Journal of the American Medical Association
12.01.2024
This Medical News article discusses 2 new observational studies that examined associations with SARS-CoV-2 antiviral medications and long COVID.
BMC Infectious Diseases
4.01.2024
. Abstract. . Purpose. To explore the effect of azvudine as compared to paxlovid for oral treatment of hospitalized patients with SARS-CoV-2 infection. . . . Methods. We analyzed data from a cohort of patients with SARS-CoV-2 infection in Shandong provincial hospital between February 15 and March 15, 2023. The primary outcome was time to sus…
Journal of Medical Virology
1.08.2023
Journal of Medical Virology, Volume 95, Issue 8, August 2023.
Journal of the American Medical Association
28.06.2023
A combination of oral nirmatrelvir and ritonavir tablets, marketed as Paxlovid, recently received full US Food and Drug Administration (FDA) approval for managing mild to moderate COVID-19 infections in adults who are at high risk of developing severe disease. Paxlovid was previously granted Emergency Use Authorization in December 2021.
Journal of Medical Virology
8.06.2023
Journal of Medical Virology, Volume 95, Issue 6, June 2023.
Journal of the American Medical Association
1.03.2023
Patients with mild to moderate COVID-19 who were treated for 5 days with VV116, an investigational oral antiviral drug that is active against SARS-CoV-2, recovered as quickly from infection as did those treated with nirmatrelvir-ritonavir (Paxlovid), according to the results of a randomized noninferiority trial published in the New England Journal of Medicine.
Journal of Medical Virology
29.12.2022
Journal of Medical Virology, Accepted Article.
Journal of Medical Virology
28.12.2022
Journal of Medical Virology, Accepted Article.
Journal of the American Medical Association
13.12.2022
Patients from certain racial and ethnic groups who sought outpatient care for COVID-19 were about 20% to 36% less likely to be prescribed Paxlovid (nirmatrelvir-ritonavir), a multi-institution study found.
Journal of the American Medical Association
4.10.2022
The FDA has updated a checklist designed to help evaluate potential drug interactions and other patient factors before prescribing Paxlovid (copackaged nirmatrelvir and ritonavir tablets) for COVID-19. It incorporates additional guidance on drugs that should not be taken with Paxlovid or may require dose or other treatment adjustments.
Journal of the American Medical Association
6.09.2022
Expiration dates have been extended from 9 months after manufacture to 12 months for 4 lots of the COVID-19 antiviral therapy Paxlovid, which consists of copackaged nirmatrelvir tablets and ritonavir tablets.
Clinical Infectious Diseases
17.08.2022
Journal of the American Medical Association
26.07.2022
Hospitalizations and emergency department visits for rebounding COVID-19 symptoms are rare after treatment with the antiviral therapy nirmatrelvir-ritonavir, according to a CDC analysis of electronic medical records from a large health care system.
Lancet Infectious Diseases
15.07.2022
The omicron variant of SARS-CoV-2 has been reported in Shanghai, China, since March 2022. In two months, the emergence of the omicron variant has resulted in 600 000 infections and about 500 deaths, especially in older people with comorbidities.1
Journal of the American Medical Association
28.06.2022
This Medical News feature examines the unexpected phenomenon of symptoms and positive test results recurring in Paxlovid users who’d a few days earlier felt fine and tested negative.
Clinical Infectious Diseases
2.06.2022
AbstractBackgroundPaxlovid was granted emergency use authorization for the treatment of mild to moderate COVID-19, based on the interim analysis of EPIC-HR trial. Paxlovid effectiveness needs to be assessed in a noncontrolled setting. In this study we used population-based real world data to evaluate the effectiveness of Paxlovid.MethodsThe database of the largest healthcare provider in Israel was used to identify all adults aged 18 years or older with first ever positive test for SARS-CoV-2 between January…
Lancet Respiratory Medicine
25.05.2022
In comments to Bloomberg published on May 3, 2022, Pfizer chief executive officer Albert Bourla suggested that patients who experience a relapse of symptoms after finishing a course of the company's COVID-19 antiviral, Paxlovid, should take a second course of the drug. Yet the emergency use authorisation issued by the US Food and Drug Administration (FDA) stipulates that Paxlovid is “not authorized for use longer than five consecutive days”. On May 4, John Farley, director of the Office of Infectious Di…
Journal of Medical Virology
22.12.2021
Journal of Medical Virology, Accepted Article.
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Medscape Infectious Diseases
5.04.2024
Clinicians should still consider prescribing the drug to adults over age 65 or those who are immunocompromised, experts said. . Medscape Medical News
Medscape Infectious Diseases
15.02.2024
The EMA has warned that Paxlovid should only be administered alongside tacrolimus, ciclosporin, everolimus, or sirolimus if their blood levels can be closely monitored. . Medscape Medical News
Medscape Infectious Diseases
31.10.2023
With the exception of venous thromboembolism and pulmonary embolism events, the antiviral drug did not reduce the incidence of post-COVID-19 conditions in a study of nearly 10,000 US veterans. . Medscape Medical News
Medscape Infectious Diseases
10.10.2023
The use of nirmatrelvir–ritonavir (Paxlovid) is associated with a lower risk for death or hospitalization in extremely vulnerable patients with COVID-19. Low-risk patients do not appear to benefit. . Medscape Medical News
Medscape Infectious Diseases
23.09.2023
A real-world study found that Pfizer's COVID-19 antiviral Paxlovid is now less effective at preventing hospitalization or death in high-risk patients as compared with earlier studies. . WebMD Health News
Medscape Infectious Diseases
20.09.2023
The American College of Physicians has issued an updated version of its living, rapid practice point guideline on the best treatment options for outpatients with confirmed COVID-19. . MDedge News
ProMED
30.05.2023
COVID-19 -- ChinaIn 2020, Catalonia saw 340 608 COVID-19 cases, among which there were 47 174 COVID-19-related hospitalizations (14%), 4,699 ICU admissions (1.4%), and 10 001 COVID-19-related deaths (3.0%). The median hospital stay was 7 days.Overall, higher annual average exposure to particle matter and nitrogen dioxide was associated with a greater risk (hazard) of COVID-19-related events. An increase in exposure to particle matter of 3.2 µg/m3 was associated with a 25% increase in hospital admissions
Medscape Infectious Diseases
18.03.2023
FDA advisers on Thursday overwhelmingly backed full approval of Pfizer's oral antiviral COVID-19 treatment Paxlovid for adults at high risk of progression to severe disease. . Reuters Health Information
Medscape Infectious Diseases
16.02.2023
The findings offer clarity amid concerns that the use of Paxlovid increased the risk for COVID-19 rebound. . WebMD Health News
Medscape Infectious Diseases
15.02.2023
The research team observed a potential decrease in effectiveness over time, and one author called for continued monitoring. . Medscape Medical News
Medscape Infectious Diseases
20.01.2023
COVID-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older. . Kaiser Health News
Medscape Infectious Diseases
19.01.2023
Evidence suggests Paxlovid can improve COVID-related outcomes, so why aren't more physicians, nurse practitioners, physician assistants, and pharmacists prescribing the antiviral combination. . Medscape Medical News
Medscape Infectious Diseases
8.12.2022
The federal government soon will stop paying for the COVID drug that has proved to be the most effective at keeping patients alive and out of the hospital. . Kaiser Health News
Morbidity and Mortality Weekly Report (MMWR)
23.11.2022
This report describes how eligible adults prescribed Paxlovid were 51% less likely to be hospitalized with COVID-19, regardless of vaccination status.
Medscape Infectious Diseases
16.11.2022
The top 3 things you should know to start your day. . 3 Things to Know Today
Medscape Infectious Diseases
15.11.2022
Dr Eric Topol says that regarding Paxlovid in COVID patients aged 60+, the evidence is compelling; we should be thinking about reasons to use it, not reasons to avoid it. . Medscape
Medscape Infectious Diseases
26.10.2022
People who took Paxlovid had a 26% reduced risk of developing symptoms of long COVID such as fatigue and shortness of breath. . WebMD Health News
Medscape Infectious Diseases
26.10.2022
A new VA study adds a third way of reducing Long COVID, no less important complications across multiple organ systems, and improved survival and avoidance of hospitalizations. It is the first such report. . Medscape
Medscape Infectious Diseases
14.10.2022
A new review paper tackles potential drug-drug interactions with the antiviral drug and today's most commonly prescribed cardiovascular drugs. .
ProMED
7.10.2022
COVID-19 --